Guangzhou Baiyunshan Pharmaceutical Holdings (00874): Tianxin Pharmaceutical has received the "Approval Notification for Supplementary Application of Sodium Cytidine Injection (2ml: 0.25g, 4ml: 0.5g)."
Baiyun Mountain (00874) announced that recently, the companys holding subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as Tianxin Pharmaceutical) received the "Approval Notice for Supplementary Application for Drugs" issued by the National Medical Products Administration for Sodium Cyclic Phosphatidic Acid Injection (2ml: 0.25g, 4ml: 0.5g).
Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its holding subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianxin Pharmaceutical"), has recently received the Approval Notice for Drug Supplement Application issued by the National Medical Products Administration for Sodium Citicoline Injection (2ml: 0.25g, 4ml: 0.5g).
The approval of the Supplement Application for Sodium Citicoline Injection (2ml: 0.25g, 4ml: 0.5g) allows Tianxin Pharmaceutical to expand the specifications of this product and pass the consistency evaluation of quality and efficacy for generic drugs, which is beneficial for enhancing the market competitiveness of this product.
Related Articles
CHINA ORAL IND (08406) has completed the issuance of a total of 328 million subscription shares, raising approximately 18.29 million HKD.
SUN HUNG KAI CO (00086) will distribute an interim dividend of HK$0.13 per share on September 21.
YTO INTL EXP (06123): Wang Lixiu resigned as a non-executive director.
CHINA ORAL IND (08406) has completed the issuance of a total of 328 million subscription shares, raising approximately 18.29 million HKD.
SUN HUNG KAI CO (00086) will distribute an interim dividend of HK$0.13 per share on September 21.
YTO INTL EXP (06123): Wang Lixiu resigned as a non-executive director.
RECOMMEND
